Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Refractory immune-mediated colitis: Fecal transplant may be the answer
WASHINGTON – FMT shows promise for the treatment of refractory immune checkpoint inhibitor–associated colitis.
News
MBDA score predicts, tracks RA patients’ responses to tofacitinib and rituximab
CHICAGO – Multibiomarker disease activity score predicts RA patients’ responses to tofacitinib and tracks rituximab responses.
News
Leflunomide-hydroxychloroquine combo shows promise in primary Sjögren’s pilot study
CHICAGO – Randomized, placebo-controlled trial may support evidence for an added benefit of the two drugs together.
News
Cervical cancer survival higher with open surgery in LACC trial
Cervical cancer was more likely to recur and survival rates were lower with minimally invasive surgery.
News
Endoscopy-related infections found higher than expected, prophylaxis overused
ATLANTA – “The potential for this becoming a bit of a monster is enhanced by the widespread use of prophylactic...
News
Case review: Posttransplant lupus nephritis recurrence rates declining
CHICAGO – Posttransplant lupus nephritis recurrence rate may be down in era of improved immunosuppression regimens.
News
PCI safely improves iPFS and OS in advanced NSCLC
TORONTO –
News
PET/CT has good accuracy for diagnosing GCA
CHICAGO – PET/CT has good diagnostic accuracy versus temporal artery biopsy for newly suspected GCA, particularly in low to moderate risk patients...
News
DETERRED trial: Concurrent atezolizumab, CRT shows promise in LA-NSCLC
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...